MVCD6
MCID: MCR130
MIFTS: 41

Microvascular Complications of Diabetes 6 (MVCD6)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 6

MalaCards integrated aliases for Microvascular Complications of Diabetes 6:

Name: Microvascular Complications of Diabetes 6 56 73 29 13 6 39
Diabetic Nephropathy 73 71
Mvcd6 56 73
Microvascular Complications of Diabetes, Susceptibility to, 6 56
Nephropathy, Diabetic, Susceptibility to 56
Nephropathy, Diabetic 56

Classifications:



External Ids:

OMIM 56 612634
OMIM Phenotypic Series 56 PS603933
MeSH 43 D048909
UMLS 71 C0011881

Summaries for Microvascular Complications of Diabetes 6

UniProtKB/Swiss-Prot : 73 Microvascular complications of diabetes 6: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 6, also known as diabetic nephropathy, is related to atherosclerosis, premature, with deafness, nephropathy, diabetes mellitus, photomyoclonus, and degenerative neurologic disease and microvascular complications of diabetes 3. An important gene associated with Microvascular Complications of Diabetes 6 is SOD2 (Superoxide Dismutase 2). The drugs Pioglitazone and Zaleplon have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and pancreas.

More information from OMIM: 612634 PS603933

Related Diseases for Microvascular Complications of Diabetes 6

Diseases in the Microvascular Complications of Diabetes 5 family:

Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 3 Microvascular Complications of Diabetes 4
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 6 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 422)
# Related Disease Score Top Affiliating Genes
1 atherosclerosis, premature, with deafness, nephropathy, diabetes mellitus, photomyoclonus, and degenerative neurologic disease 12.3
2 microvascular complications of diabetes 3 12.1
3 microvascular complications of diabetes 7 12.0
4 microvascular complications of diabetes 4 11.9
5 microvascular complications of diabetes 5 11.6
6 diabetic angiopathy 11.6
7 microvascular complications of diabetes 1 11.4
8 microvascular complications of diabetes 2 11.4
9 end stage renal failure 10.6
10 fibrosis of extraocular muscles, congenital, 1 10.6
11 hypertension, essential 10.5
12 iga glomerulonephritis 10.5
13 arteriosclerosis 10.4
14 autonomic neuropathy 10.4
15 hyperglycemia 10.4
16 kidney hypertrophy 10.4
17 pre-eclampsia 10.4
18 diabetic neuropathy 10.4
19 atherosclerosis susceptibility 10.3
20 hypercholesterolemia, familial, 1 10.3
21 nephrosclerosis 10.3
22 hyperuricemia 10.3
23 cytokine deficiency 10.3
24 hypoglycemia 10.3
25 proteasome-associated autoinflammatory syndrome 1 10.3
26 kidney disease 10.3
27 congestive heart failure 10.3
28 yemenite deaf-blind hypopigmentation syndrome 10.3
29 glucose intolerance 10.3
30 rickets 10.3
31 arteries, anomalies of 10.3
32 hypertriglyceridemia, familial 10.3
33 wilms tumor 5 10.3
34 hyperlipoproteinemia, type iii 10.3
35 coronary artery anomaly 10.3
36 focal segmental glomerulosclerosis 10.3
37 diabetes mellitus 10.3
38 rapidly involuting congenital hemangioma 10.3
39 systemic lupus erythematosus 10.2
40 homocysteinemia 10.2
41 creatinine clearance quantitative trait locus 10.2
42 deficiency anemia 10.2
43 lipoid nephrosis 10.2
44 cardiovascular system disease 10.2
45 b-cell lymphoma 10.2
46 arterial calcification, generalized, of infancy, 1 10.2
47 eclampsia 10.2
48 lipid metabolism disorder 10.2
49 fatty liver disease 10.2
50 autoimmune disease 10.2

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 6:



Diseases related to Microvascular Complications of Diabetes 6

Symptoms & Phenotypes for Microvascular Complications of Diabetes 6

Clinical features from OMIM:

612634

Drugs & Therapeutics for Microvascular Complications of Diabetes 6

Drugs for Microvascular Complications of Diabetes 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 339)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
2
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
3
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
4
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
5
Atenolol Approved Phase 4 29122-68-7 2249
6
Methyldopa Approved Phase 4 555-30-6 38853
7
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
8
Clonidine Approved Phase 4 4205-90-7 2803
9
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
10
Capsaicin Approved Phase 4 404-86-4 1548943
11
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
12
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
13
Probucol Approved, Investigational Phase 4 23288-49-5 4912
14
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
15
Ramipril Approved Phase 4 87333-19-5 5362129
16
Zinc Approved, Investigational Phase 4 7440-66-6 32051
17
Doxazosin Approved Phase 4 74191-85-8 3157
18
Indapamide Approved Phase 4 26807-65-8 3702
19
Atorvastatin Approved Phase 4 134523-00-5 60823
20
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
21
Trandolapril Approved Phase 4 87679-37-6 5484727
22
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
23
Nisoldipine Approved Phase 4 63675-72-9 4499
24
Insulin glargine Approved Phase 4 160337-95-1
25
Insulin glulisine Approved Phase 4 207748-29-6
26
Liraglutide Approved Phase 4 204656-20-2 44147092
27
Nitric Oxide Approved Phase 4 10102-43-9 145068
28
Allopurinol Approved Phase 4 315-30-0 2094
29
Insulin lispro Approved Phase 4 133107-64-9
30
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
31
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
32
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
33
Glimepiride Approved Phase 4 93479-97-1 3476
34
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
35
Febuxostat Approved Phase 4 144060-53-7 134018
36
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
37
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
38
Canagliflozin Approved Phase 4 842133-18-0
39
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
40
Amlodipine Approved Phase 4 88150-42-9 2162
41
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
42
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
43
Gliclazide Approved Phase 4 21187-98-4 3475
44
Hydralazine Approved Phase 4 86-54-4 3637
45
Terazosin Approved Phase 4 63590-64-7 5401
46
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
47
Metformin Approved Phase 4 657-24-9 14219 4091
48
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
49
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
50
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6, 59-43-8 1130

Interventional clinical trials:

(show top 50) (show all 387)
# Name Status NCT ID Phase Drugs
1 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
2 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
3 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
4 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
5 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
6 Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
7 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
8 A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy Unknown status NCT02314533 Phase 4 fenofibrate
9 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
10 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study Unknown status NCT02690883 Phase 4 Exenatide;Lispro
11 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
12 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
13 A Study on the Anti-proteinuric Effects of Pioglitazone in Patients With Type 2 Diabetes. Unknown status NCT00749047 Phase 4 Pioglitazone
14 Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients Unknown status NCT00541853 Phase 4 Candesartan;Candesartan and Cilnidipine;Candesartan plus non-CCB agents
15 Phase IV, Effect of Rennin-Angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria--- A Randomized Controlled Trial Unknown status NCT01500590 Phase 4 Renin-angiotensin system blockers;non-renin angiotensin system blockers
16 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Unknown status NCT00535925 Phase 4 current therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
17 The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART) Unknown status NCT00202618 Phase 4 Valsartan;Amlodipine
18 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
19 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
20 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
21 Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus Completed NCT00419835 Phase 4 enalapril;losartan
22 A Trial of Telmisartan Prevention of Cardiovascular Disease Completed NCT01075698 Phase 4 Non-ARB (standard therapy);ARB (Telmisartan)
23 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone
24 A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy Completed NCT01252056 Phase 4 Probucol;Probucol and Cilostazol
25 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Completed NCT03147677 Phase 4 Alfacalcidol;Irbesartan
26 A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy Completed NCT00565318 Phase 4 Benfotiamine;Placebo
27 Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy Completed NCT00295555 Phase 4 Effects of doxazosin on morning surge in diabetic patients
28 Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
29 A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy Completed NCT00573430 Phase 4 Candesartan Cilexetil;Candesartan Cilexetil;Candesartan Cilexetil 32mg
30 A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study - Completed NCT00153088 Phase 4 Telmisartan capsule 40 mg;Placebo;Telmisartan capsule 80 mg
31 A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy Completed NCT00234871 Phase 4 trandolapril/verapamil;Lotrel (amlodipine/benazepril)
32 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4 nisoldipine;lisinopril
33 Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) Completed NCT00708981 Phase 4
34 "Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study" Completed NCT01028287 Phase 4 ACTH;ACTH
35 A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients Completed NCT01664676 Phase 4 Liraglutide;Placebo-liraglutide
36 Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria Completed NCT00893425 Phase 4 ramipril
37 A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT) Completed NCT00235014 Phase 4 trandolapril;trandolapril/verapamil;placebo;verapamil
38 A Multicenter, Randomized, Open-label, Parallel-group, Diabetic Diet-controlled Study to Evaluate the Efficacy and Safety of Compound α-Keto Acid Tablet in Combination With LPD in Delaying the Progress of Type 2 Diabetic Nephropathy Completed NCT00363987 Phase 4 Ketosteril®
39 A Double-blind, Randomized, Placebo Controlled Trial of Allopurinol in Patients With Type 1 Diabetes and Microalbuminuria Completed NCT02829177 Phase 4 Allopurinol;Placebo
40 Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy Completed NCT00276133 Phase 4 Effects of atorvastatin versus probucol on small dense LDL
41 A Randomised, Double-Blind, Placebo-Controlled Study of Cilostazol 100 mg Twice Daily in the Treatment of Diabetic Nephropathy in Hong Kong Chinese Completed NCT00272831 Phase 4 Cilostazol;Placebo
42 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients Completed NCT02628106 Phase 4 Lipo-PGE1
43 Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up Completed NCT00171574 Phase 4 Valsartan;Valsartan plus HCTZ;Lisinopril
44 The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy Completed NCT01331317 Phase 4 Paricalcitol
45 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial Completed NCT02502071 Phase 4 sodium bicarbonate
46 FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients Completed NCT01703234 Phase 4 Ramipril
47 The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combine Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension Completed NCT00921570 Phase 4 Amlodipine;Valsartan
48 Effect of Calcium Channel Blocker on the Serum Fibrobalst Growth Factor-23 (FGF-23) Levels in Type-2 Diabetic Patients With Proteinuria Purpose Completed NCT01738945 Phase 4 Amlodipine
49 A Single Arm Open Label Multicenter Interventional Study to Assess the Efficacy, Safety, and Tolerability of Every 4 Weeks Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Diabetic Nephropathy With Chronic Kidney Disease Stages III-IV Not on Dialysis, Not Currently Treated With ESA. Completed NCT01191983 Phase 4 Methoxy polyethylene glycol-epoetin beta [Mircera]
50 A Phase 4, Monocenter, Randomized, Double-blind, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Linagliptin Versus the Sulfonylurea (SU) Derivative Glimepiride on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus (T2DM) Completed NCT02106104 Phase 4 Linagliptin 5 mg QD (N=24);Glimepiride 1 mg QD (N=24)

Search NIH Clinical Center for Microvascular Complications of Diabetes 6

Inferred drug relations via UMLS 71 / NDF-RT 50 :


benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan

Genetic Tests for Microvascular Complications of Diabetes 6

Genetic tests related to Microvascular Complications of Diabetes 6:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 6 29 SOD2

Anatomical Context for Microvascular Complications of Diabetes 6

MalaCards organs/tissues related to Microvascular Complications of Diabetes 6:

40
Kidney, Endothelial, Pancreas, Bone, Heart, Liver, Monocytes

Publications for Microvascular Complications of Diabetes 6

Articles related to Microvascular Complications of Diabetes 6:

(show top 50) (show all 17758)
# Title Authors PMID Year
1
A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy. 61 56 6
17192491 2007
2
The polymorphism of manganese superoxide dismutase is associated with diabetic nephropathy in Japanese type 2 diabetic patients. 61 56 6
12624725 2003
3
Genotype-activity relationship for Mn-superoxide dismutase, glutathione peroxidase 1 and catalase in humans. 56 6
16538174 2006
4
The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. 6
15591282 2004
5
Polymorphisms in the SOD2 and HLA-DRB1 genes are associated with nonfamilial idiopathic dilated cardiomyopathy in Japanese. 6
10425186 1999
6
On signal sequence polymorphisms and diseases of distribution. 6
8633092 1996
7
Long non-coding RNA MALAT1 and microRNA-499a expression profiles in diabetic ESRD patients undergoing dialysis: a preliminary cross-sectional analysis. 61
30270667 2020
8
miR-218 regulates diabetic nephropathy via targeting IKK-β and modulating NK-κB-mediated inflammation. 61
31549412 2020
9
Metformin reduces TRPC6 expression through AMPK activation and modulates cytoskeleton dynamics in podocytes under diabetic conditions. 61
31778750 2020
10
Keap1/Nrf2/ARE signaling unfolds therapeutic targets for redox imbalanced-mediated diseases and diabetic nephropathy. 61
31945695 2020
11
Effects of Cytotoxic T Lymphocyte-Associated Antigen 4 Immunoglobulin Combined with Microbubble-Mediated Irradiation on Hemodynamics of the Renal Artery in Rats with Diabetic Nephropathy. 61
31864804 2020
12
Smad4 promotes diabetic nephropathy by modulating glycolysis and OXPHOS. 61
31916354 2020
13
Smad3 signaling affects high glucose-induced podocyte injury via regulation of the cytoskeletal protein transgelin. 61
32034833 2020
14
Heterogeneity in patterns of progression of chronic kidney disease. 61
32034854 2020
15
BML-111 attenuates high glucose-induced inflammation, oxidative stress and reduces extracellular matrix accumulation via targeting Nrf2 in rat glomerular mesangial cells. 61
31881376 2020
16
Inhibition of NADPH Oxidase 5 (NOX5) Suppresses High Glucose-Induced Oxidative Stress, Inflammation and Extracellular Matrix Accumulation in Human Glomerular Mesangial Cells. 61
32012145 2020
17
Renal Lipid Metabolism and Lipotoxicity in Diabetes. 61
32039770 2020
18
Transcriptional Regulation of Transforming Growth Factor β1 by Glucose: Investigation into the Role of the Hexosamine Biosynthesis Pathway. 61
32039769 2020
19
Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. 61
31940200 2020
20
Protection of diabetes-induced kidney injury by phosphocreatine via the regulation of ERK/Nrf2/HO-1 signaling pathway. 61
31899224 2020
21
GdCl3 attenuates the glomerular sclerosis of streptozotocin (STZ) induced diabetic rats via inhibiting TGF-β/Smads signal pathway. 61
31831259 2020
22
Acute and chronic glomerular damage is associated with reduced CD133 expression in urinary extracellular vesicles. 61
31869243 2020
23
Downregulation of MiR-218 can alleviate high-glucose-induced renal proximal tubule injury by targeting GPRC5A. 61
32028854 2020
24
Connexin-mediated cell communication in the kidney: A potential therapeutic target for future intervention of diabetic kidney disease?: Joan Mott Prize Lecture. 61
31785013 2020
25
DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment. 61
31385198 2020
26
Silencing CCNG1 protects MPC-5 cells from high glucose-induced proliferation-inhibition and apoptosis-promotion via MDM2/p53 signaling pathway. 61
32016904 2020
27
Risk Factors and Outcomes of Cerebral Stroke in End-Stage Renal Disease Patients Receiving Hemodialysis. 61
32037266 2020
28
Glucagon-Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T-Cell Proliferation. 61
31759969 2020
29
Renoprotective effects of Gushen Jiedu capsule on diabetic nephropathy in rats. 61
32029775 2020
30
Salidroside ameliorates diabetic nephropathy in rats by activating renal AMPK/SIRT1 signaling pathway. 61
32030786 2020
31
Implications of IgG deposit in glomeruli in Chinese patients with diabetic nephropathy. 61
32031751 2020
32
Gold nanoparticles attenuate albuminuria by inhibiting podocyte injury in a rat model of diabetic nephropathy. 61
31637677 2020
33
TGF-β and Diabetic Nephropathy: Lessons Learned Over the Past 20 Years. 61
32039767 2020
34
Effects of dietary protein intake on renal outcome and mortality in patients with advanced diabetic nephropathy. 61
31587125 2020
35
Enhancing kidney DDAH-1 expression by adenovirus delivery reduces ADMA and ameliorates diabetic nephropathy. 61
31904280 2020
36
Whole-Genome Sequencing of Finnish Type 1 Diabetic Siblings Discordant for Kidney Disease Reveals DNA Variants associated with Diabetic Nephropathy. 61
31919106 2020
37
Association of diabetic nephropathy with the severity of obstructive sleep apnea-hypopnea syndrome in patients with type 2 diabetes mellitus. 61
32023571 2020
38
C-C chemokine receptor type 2 mediates glomerular injury and interstitial fibrosis in focal segmental glomerulosclerosis. 61
30597038 2020
39
Protective effect and possible mechanisms of ligustrazine isolated from Ligusticum wallichii on nephropathy in rats with diabetes: A preclinical systematic review and meta-analysis. 61
31978520 2020
40
Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review. 61
32005442 2020
41
Differential contribution of Nox1, Nox2 and Nox4 to kidney vascular oxidative stress and endothelial dysfunction in obesity. 61
31563085 2020
42
Insulin Resistance in Type 1 Diabetes Mellitus and Its Association with Patient's Micro- and Macrovascular Complications, Sex Hormones, and Other Clinical Data. 61
31792784 2020
43
Protective effects of Croton hookeri on streptozotocin-induced diabetic nephropathy. 61
31600566 2020
44
NLRP3 inflammasome negatively regulates podocyte autophagy in diabetic nephropathy. 61
31703838 2020
45
A protective role of renalase in diabetic nephropathy. 61
31899483 2020
46
Analysis for warning factors of type 2 diabetes mellitus complications with Markov blanket based on a Bayesian network model. 61
31923820 2020
47
The Long-Term Incidence of Hospitalization for Ketoacidosis in Adults with Established T1D-A Prospective Cohort Study. 61
31529090 2020
48
Lisinopril-Induced Angioedema in a Patient with Plasma Prekallikrein Deficiency. 61
31984307 2020
49
Diabetic Nephropathy: An Overview. 61
31701441 2020
50
Pharmacological Management of Diabetic Nephropathy. 61
30961500 2020

Variations for Microvascular Complications of Diabetes 6

ClinVar genetic disease variations for Microvascular Complications of Diabetes 6:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SOD2 NM_000636.4(SOD2):c.47T>C (p.Val16Ala)SNV drug response 14751 rs4880 6:160113872-160113872 6:159692840-159692840

Expression for Microvascular Complications of Diabetes 6

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 6.

Pathways for Microvascular Complications of Diabetes 6

GO Terms for Microvascular Complications of Diabetes 6

Sources for Microvascular Complications of Diabetes 6

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....